Can Fite BioPharma (CANFY)

Can-Fite BioPharma is an Israeli biopharmaceutical company focused on developing innovative drug candidates for the treatment of various diseases, including cancer, liver, and inflammatory conditions. Their core technology utilizes the A3 adenosine receptor (A3AR) as a therapeutic target. The company has a pipeline of proprietary drugs, including Piclidenoson (CF101) for psoriasis and Namodenoson (CF102) for liver cancer and NASH. Their drugs are designed to be orally bioavailable with an excellent safety profile, having been tested in close to 2000 patients in clinical studies.

Can-Fite has an advanced clinical stage drug development platform and has successfully out-licensed their drugs to several pharmaceutical companies worldwide. They are actively pursuing further clinical trials and partnerships to expand their reach and impact the treatment of significant unmet medical needs.

Can-Fite BioPharma is an Israeli biopharmaceutical company dedicated to developing novel therapies for multi-billion dollar markets in oncology, liver, and inflammatory diseases. Their platform technology focuses on the A3 adenosine receptor (A3AR), a target highly expressed in pathological cells, with the goal of developing safe and effective oral drugs that modulate this receptor to treat a range of conditions. Can-Fite has a pipeline of proprietary drug candidates in clinical development, including Namodenoson for liver cancer, Piclidenoson for psoriasis, and CF602 for erectile dysfunction, demonstrating their commitment to addressing unmet medical needs.

Can-Fite BioPharma promotes a culture of innovation and collaboration, centered around its commitment to developing novel therapies for serious diseases. The company emphasizes a strong work ethic and dedication to scientific excellence, while also fostering a supportive and inclusive environment where employees can contribute their diverse skills and perspectives. Can-Fite prioritizes a collaborative approach to drug development, bringing together a team of experienced scientists and professionals to advance its pipeline of promising drug candidates.